Ovarian Cancer study: XmAb541
Official title Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06276491
What this study is testing
What is XmAb541?
an investigational monoclonal bispecific antibody being studied as a potential treatment for ovarian cancer is designed to bind both a tumor‑associated antigen and immune‑cell receptors to help the immune system recognize and attack cancer cells
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will find out if XmAb541 is safe and well tolerated and determine a safe dose for future research. It will also look at any effect on the tumors.
- Who it's for
- Adults who have advanced ovarian cancer, endometrial cancer, or germ cell tumors.
- What's involved
- Participants will receive XmAb541 at varying doses and undergo regular clinic visits and tests to check safety and tumor response.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 15 and older
You may be able to join if
- Age ≥ 18 years. For US only: people with GCTs, age ≥15 years
- CLDN6+ tumor
- Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma...
- Adequate Eastern Cooperative Oncology Group performance status
- Life expectancy ≥ 3 months
You likely can't join if
- Participants with untreated brain metastases are excluded. Participants with treated brain metastases may participate, provided they are...
- Active known or suspected autoimmune disease
- Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days...
- Clinically significant cardiovascular, pulmonary or gastrointestinal disease
- Active hepatitis B or hepatitis C
See the full eligibility criteria
- Age ≥ 18 years. For US only: people with GCTs, age ≥15 years
- CLDN6+ tumor
- Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma...
- Adequate Eastern Cooperative Oncology Group performance status
- Life expectancy ≥ 3 months
- Adequate liver, kidney, and bone marrow function Key
- Participants with untreated brain metastases are excluded. Participants with treated brain metastases may participate, provided they are radiologically stable.
- Active known or suspected autoimmune disease
- Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug
- Clinically significant cardiovascular, pulmonary or gastrointestinal disease
- Active hepatitis B or hepatitis C
The study team makes the final eligibility decision.
Where it is enrolling
- Duarte, California, United States
- Palo Alto, California, United States
- San Francisco, California, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Indianapolis, Indiana, United States
- Detroit, Michigan, United States
- Minneapolis, Minnesota, United States
- Hackensack, New Jersey, United States
- New York, New York, United States
- The Bronx, New York, United States
- Columbus, Ohio, United States
- Oklahoma City, Oklahoma, United States
- Pittsburgh, Pennsylvania, United States
- Nashville, Tennessee, United States
- Charlottesville, Virginia, United States
- Kortrijk, Belgium
- Leuven, Belgium
- Liège, Belgium
+ 6 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 15 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Duarte, California, United States; Palo Alto, California, United States; San Francisco, California, United States; Tampa, Florida, United States; Atlanta, Georgia, United States; Chicago, Illinois, United States and 20 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.